<DOC>
	<DOCNO>NCT01984736</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetics EVP-6124 metabolite single oral dose subject mild , moderate severe hepatic impairment compare subject normal hepatic function .</brief_summary>
	<brief_title>EVP-6124 Hepatic Impairment Study</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Adult male female subject age 18 65 year ( inclusive ) . Able understand willing sign Informed Consent Form able comply study restriction . Females may enroll : 1. document surgically sterile postmenopausal ( amenorrhoea great 1 year follicle stimulate hormone , FSH , great equal 30 mU/mL ) , 2. practice true abstinence negative urine pregnancy test Screening Day 1 , 3. use double barrier contraception protection , one physical barrier method , adequate hormonal method ( eg , contraceptive implant , injectables , oral contraceptive ) and/or nonhormonal method ( eg , intrauterine device , condom , diaphragm spermicide ) Screening least 2 week prior study drug administration ( whichever earlier ) 30 day intake study medication negative urine pregnancy test Screening Day 1 . Males partner childbearing potential may enrol : 1. document surgically sterile ( vasectomy ) , 2. practice true abstinence , 3. use adequate double barrier contraception method , one physical barrier 90 day drug intake . BMI 18.0 35.0 kg/m2 , inclusive , BMI ( kg/m2 ) = body weight ( kg ) / height2 ( m2 ) . Patients diabetes mellitus include provided disease control ( judge PI ) . Clinically relevant abnormal history , abnormal finding physical examination , vital sign , ECG , laboratory test pretrial screen assessment Investigator judge likely interfere objective trial safety volunteer except condition associate hepatic impairment subject liver cirrhosis ( Groups 1 2 ) . Surgery ( eg stomach bypass ) medical condition might significantly affect absorption medicine ( judge PI ) . Uncontrolled treated/untreated hypertension ( define mean 3 repeat measurement systolic blood pressure great equal 160 mmHg and/or diastolic blood pressure great equal 105 mmHg ) ; current document history repeat clinically significant hypotension severe episodes orthostatic hypotension ( systolic blood pressure &lt; 90 mmHg and/or diastolic blood pressure le 50 mmHg ) . History multiple and/or severe allergy drug food history severe anaphylactic reaction . Participation another investigational drug trial within 30 day prior dose ( 5 time halflife drug , whichever long ) exposure three new investigational agent within 12 month prior enrolment . Acute illness within 14 day prior dose unless mild severity approve Investigator Sponsor 's medical representative . Presence active infection require antibiotic . History cancer ( judge full remission ) presence cancer ( except basal cell skin cancer squamous cell skin cancer ) judge Investigator . Positive urine drug screen ( due concomitant medication ) alcohol breath test Screening and/or Day 1 . History drug abuse within last 2 year . Ingestion alcohol caffeine within 24 hour prior dose confinement . Regular alcohol consumption must exceed 21 unit male 14 unit female per week ( 1 unit equal 340 mL beer , 115 mL wine 43 mL spirit ) . Smoking 10 cigarette equivalent per day . Concomitant use medication know strong cytochrome ( CYP ) P450 inducer inhibitor within 21 day prior study drug administration . Consumption grapefruit , grapefruit juice , pomelo , Seville oranges within 7 day prior study drug administration study conduct . Positive serology antiHuman immunodeficiency virus subtype 1 2 . Loss 450 mL blood 3 month trial ( eg , blood donor ) . Female subject pregnant , nursing , plan become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Safety</keyword>
</DOC>